Anti-Parasitic Drug Kills COVID-19 in Lab
SPECIAL FEATURE, 6 Apr 2020
4 Apr 2020 – An anti-parasitic drug available throughout the world has been found to kill COVID-19 in the lab within 48 hours.
A Monash University-led study has shown a single dose of the drug Ivermectin could stop the SARS-CoV-2 virus growing in cell culture.
“We found that even a single dose could essentially remove all viral RNA (effectively removed all genetic material of the virus) by 48 hours and that even at 24 hours there was a really significant reduction in it,” Monash Biomedicine Discovery Institute’s Dr Kylie Wagstaff said on Friday.
While it’s not known how Ivermectin works on the virus, the drug likely stops the virus dampening the host cells’ ability to clear it.
The next step is for scientists to determine the correct human dosage, to make sure the level used in vitro is safe for humans.
“In times when we’re having a global pandemic and there isn’t an approved treatment, if we had a compound that was already available around the world then that might help people sooner,” Dr Wagstaff said.
“Realistically it’s going to be a while before a vaccine is broadly available.”
Before Ivermectin can be used to combat coronavirus, funding is needed to get it to pre-clinical testing and clinical trials.
Ivermectin is an FDA-approved anti-parasitic drug also shown to be effective in vitro against viruses including HIV, dengue and influenza.
The study is the joint work of Monash Biomedicine Discovery Institute and the Peter Doherty Institute of Infection and Immunity.
The study findings have been published in Antiviral Research.
Tags: COVID-19, Community, Compassion, Coronavirus, Economy, Empathy, Epidemics, Health, Pandemic, Public Health, Science, Science and Medicine, Sharing, Trade, United Nations, WHO, World
DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
Join the discussion!
We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.